{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:30:58Z","timestamp":1770895858929,"version":"3.50.1"},"reference-count":69,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,30]],"date-time":"2021-05-30T00:00:00Z","timestamp":1622332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Age-related macular degeneration (AMD) is one of the most common causes of vision loss. Advanced forms of AMD are seen in primarily two types\u2014neovascular AMD (nAMD) with the presence of choroid neovascularization and non-neovascular AMD (nnAMD) with geographic atrophy. Neovascular AMD is characterized by choroidal neovascularization (CNV), which leads to a cascade of complications, including exudation, leakage, and ultimately fibrosis with photoreceptor loss. Inhibition of VEGF represents the current standard of care. However, there is a tremendous gap between the outcomes in randomized clinical trials and real-world settings. New agents for nAMD might offer the potential to improve treatment outcomes and reduce treatment of frequent intravitreal injections. We summarize all the newer molecules, their pivotal clinical trial results, and their unique mechanisms of action; these include longer-acting agents, combination strategies, sustained release, and genetic therapies.<\/jats:p>","DOI":"10.3390\/jcm10112436","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T01:51:37Z","timestamp":1622425897000},"page":"2436","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)"],"prefix":"10.3390","volume":"10","author":[{"given":"Prem","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veeral","family":"Sheth","sequence":"additional","affiliation":[{"name":"University Retina and Macula Associates, Oak Forest, IL 60452, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archophthalmol.2010.318","article-title":"Prevalence of age-related macular degeneration in the US population","volume":"129","author":"Klein","year":"2011","journal-title":"Arch. Ophthal."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1001\/jama.2009.729","article-title":"Forecasting age-related macular degeneration through 2050","volume":"301","author":"Klein","year":"2009","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/bjophthalmol-2017-311258","article-title":"Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: Magnitude, temporal trends and projections","volume":"102","author":"Bourne","year":"2018","journal-title":"Br. J. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical Classification of Age-related Macular Degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kolar, P. (2013). Classification and clinical features of AMD. Age-Related Macular Degeneration-Etiology, Diagnosis and Management\u2014A Glance at the Future, InTech.","DOI":"10.5772\/53762"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4103\/2008-322X.150799","article-title":"Choroidal Neovascularization Induces Retinal Edema and its Treatment Addresses this Problem","volume":"9","author":"Tadayoni","year":"2014","journal-title":"J. Ophthalmic. Vis. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/archopht.1986.01050170092029","article-title":"Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity","volume":"104","author":"Guyer","year":"1986","journal-title":"Arch. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: A systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"ref_10","first-page":"CD004763","article-title":"Laser photocoagulation for neovascular age-related macular degeneration","volume":"18","author":"Virgili","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","article-title":"Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cox, J.T., Eliott, D., and Sobrin, L. (2021). Inflammatory Complications of Intravitreal Anti-VEGF Injections. J. Clin. Med., 10.","DOI":"10.3390\/jcm10050981"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ophtha.2017.07.005","article-title":"Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration","volume":"125","author":"Daien","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/09286586.2015.1122067","article-title":"Intraocular Inflammation Following Intravitreal Injection of Anti-VEGF Medications for Neovascular Age-Related Macular Degeneration","volume":"23","author":"Knickelbein","year":"2016","journal-title":"Ophthalmic Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"13248","DOI":"10.1038\/s41598-020-70269-7","article-title":"The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: A systematic review and meta-analysis","volume":"10","author":"Bassil","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1350-9462(01)00010-6","article-title":"An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch\u2019s membrane interface in aging and age-related macular degeneration","volume":"20","author":"Hageman","year":"2001","journal-title":"Prog. Retin Eye Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1038\/s41467-019-11262-1","article-title":"A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration","volume":"10","author":"Handa","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archopht.122.4.598","article-title":"Current concepts in the pathogenesis of age-related macular degeneration","volume":"122","author":"Zarbin","year":"2004","journal-title":"Arch Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16939","DOI":"10.1074\/jbc.M808166200","article-title":"Oxidative Stress Renders Retinal Pigment Epithelial Cells Susceptible to Complement-mediated Injury","volume":"284","author":"Thurman","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"22414","DOI":"10.1074\/jbc.M702321200","article-title":"Oxidative Stress Modulates Complement Factor H Expression in Retinal Pigmented Epithelial Cells by Acetylation of FOXO","volume":"282","author":"Wu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ng1750","article-title":"Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration","volume":"38","author":"Gold","year":"2006","journal-title":"Nat. Genetics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/IAE.0b013e3181f57e30","article-title":"Pathway-based therapies for age-related macular degeneration: An integrated survey of emerging treatment alternatives","volume":"30","author":"Zarbin","year":"2010","journal-title":"Retina"},{"key":"ref_27","first-page":"353","article-title":"Age-related macular degeneration (AMD): Pathogenesis and therapy","volume":"58","author":"Nowak","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9394(02)01624-0","article-title":"A role for local inflammation in the formation of drusen in the aging eye","volume":"134","author":"Anderson","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.canlet.2013.12.004","article-title":"Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression","volume":"346","author":"Li","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lieu, C.H., Tran, H., Jiang, Z.Q., Mao, M., Overman, M.J., Lin, E., Eng, C., Morris, J., Ellis, L., and Heymach, J.V. (2013). The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077117"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-010-0480-6","article-title":"Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells","volume":"104","author":"Grau","year":"2011","journal-title":"J. Neurooncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.oret.2017.04.004","article-title":"Belfort, R., Jr. Bevacizumab Injection in Patients with Neovascular Age-Related Macular Degeneration Increases Angiogenic Biomarkers","volume":"2","author":"Cabral","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Khan, M., Aziz, A.A., Shafi, N.A., Abbas, T., and Khanani, A.M. (2020). Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Cells, 9.","DOI":"10.3390\/cells9081869"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1172\/JCI84923","article-title":"Tie1 controls angiopoietin function in vascular remodeling and inflammation","volume":"126","author":"Korhonen","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"ref_36","unstructured":"(2021, April 08). Genentech Press Release. Available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2021-01-25.htm."},{"key":"ref_37","unstructured":"(2021, April 08). Genentech Press Release. Available online: https:\/\/www.roche.com\/media\/releases\/med-cor-2021-02-12.htm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/OPTH.S194234","article-title":"Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date","volume":"14","author":"Chen","year":"2020","journal-title":"Clin. Ophthalmol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: Results from the randomized phase 2 LADDER clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_40","unstructured":"(2021, April 09). EyeWire News. Available online: https:\/\/eyewire.news\/articles\/phase-3-data-show-port-delivery-system-with-ranibizumab-enabled-over-98-of-patients-to-go-6-months-between-treatments-for-wet-amd\/."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1172\/JCI80297","article-title":"Neurovascular crosstalk between interneurons and capillaries is required for vision","volume":"125","author":"Usui","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","article-title":"Macular atrophy in the HARBOR study for neovascular age-related macular degeneration","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-2836(03)00896-9","article-title":"Designing Repeat Proteins: Well-expressed, Soluble and Stable Proteins from Combinatorial Libraries of Consensus Ankyrin Repeat Proteins","volume":"332","author":"Binz","year":"2003","journal-title":"J. Mol. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.drudis.2008.04.013","article-title":"DARPins: A new generation of protein therapeutics","volume":"13","author":"Stumpp","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ajo.2012.03.047","article-title":"Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans","volume":"154","author":"Krohne","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1167\/iovs.18-25307","article-title":"Functional characterization of abicipar-pegol, an Anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability","volume":"59","author":"Rodrigues","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1089\/jop.2018.0062","article-title":"Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration","volume":"34","author":"Callanan","year":"2018","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.ophtha.2020.03.035","article-title":"Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study","volume":"127","author":"Kunimoto","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_50","unstructured":"(2021, April 09). Molecular Partners Press Release. Available online: https:\/\/www.molecularpartners.com\/allergan-and-molecular-partners-announce-topline-safety-results-from-maple-study-of-abicipar-pegol\/."},{"key":"ref_51","first-page":"75","article-title":"New therapeutic targets in the treatment of age-related macular degeneration","volume":"95","year":"2020","journal-title":"Arch. Soc. Esp. Oftalmol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: Evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_54","first-page":"3670","article-title":"Phase 1 first-in-human study of KSI-301: A novel anti-VEGF antibody biopolymer conjugate with extended durability","volume":"60","author":"Patel","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_55","unstructured":"(2021, April 09). EyeWire News. Available online: https:\/\/eyewire.news\/articles\/kodiak-sciences-announces-1-year-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-retinal-vascular-diseases\/."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","article-title":"Safety and efficacy of conbercept in neovascular age-related macular degeneration: Results from a 12-month randomized phase 2 study: AURORA study","volume":"121","author":"Li","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.exer.2011.09.002","article-title":"Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit","volume":"97","author":"Li","year":"2012","journal-title":"Exp Eye Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11095-008-9718-9","article-title":"The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization","volume":"26","author":"Zhang","year":"2009","journal-title":"Pharm. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.2147\/DDDT.S67536","article-title":"Profile of conbercept in the treatment of neovascular age-related macular degeneration","volume":"9","author":"Sun","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.oret.2019.10.008","article-title":"Phase 1 Study of OPT-302 Inhibition of Vascular Endothelial Growth Factors C and D for Neovascular Age-Related Macular Degeneration","volume":"4","author":"Dugel","year":"2020","journal-title":"Ophthalmol. Retina"},{"key":"ref_61","unstructured":"(2021, April 07). Biotech Dispatch. Available online: https:\/\/biotechdispatch.com.au\/news\/opthea-confirms-plans-and-protocols-for-late-stage-opt-302-studi."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/APO.0000000000000291","article-title":"Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020","volume":"9","author":"Samanta","year":"2020","journal-title":"Asia Pac. J. Ophthalmol. (Phila.)"},{"key":"ref_63","unstructured":"(2021, April 01). BusinessWire. Available online: https:\/\/www.businesswire.com\/news\/home\/20190121005424\/en\/Graybug-Vision-Presents-Top-Line-Results-of-Phase-12a-ADAGIO-Study-at-Hawaiian-Eye-Retina-2019."},{"key":"ref_64","unstructured":"Kaiser, P.K., and Boyer, D. (2019). Most exciting retinal drugs: 2019. Retina."},{"key":"ref_65","unstructured":"(2021, April 01). EyeWire News. Available online: https:\/\/eyewire.news\/articles\/graybug-vision-completes-treatment-phase-of-altissimo-trial-in-wet-amd-with-12-month-topline-data\/."},{"key":"ref_66","unstructured":"(2021, January 22). REGENXBIO\u2019s Gene Therapy for Wet Amd Performing Encouragingly in Human Study. Available online: https:\/\/www.fightingblindness.org\/research\/regenxbio-s-gene-therapy-for-wet-amd-performing-encouragingly-in-human-study-15."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"12260","DOI":"10.1128\/JVI.01304-07","article-title":"Structure of adeno-associated virus serotype 8, a gene therapy vector","volume":"81","author":"Nam","year":"2007","journal-title":"J. Virol."},{"key":"ref_68","unstructured":"(2021, April 01). PRNewswire. Available online: https:\/\/www.prnewswire.com\/news-releases\/regenxbio-announces-additional-positive-interim-phase-iiia-and-long-term-follow-up-data-of-rgx-314-for-the-treatment-of-wet-amd-301228344.html."},{"key":"ref_69","unstructured":"(2021, April 09). EyeWire News. Available online: https:\/\/eyewire.news\/articles\/adverum-reports-new-interim-data-from-optic-phase-1-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd\/."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/11\/2436\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:09Z","timestamp":1760162949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/11\/2436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,30]]},"references-count":69,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jcm10112436"],"URL":"https:\/\/doi.org\/10.3390\/jcm10112436","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,30]]}}}